Prognostic value of cyclooxygenase-2 and p53 expression in stage T1 grade III bladder cancer

Sung Joon Hong, Joong Shik Lee, Byung Ha Chung, Soo Mee Kwon, Sun Il Kim

Research output: Contribution to journalArticle

Abstract

Purpose: The prognostic value of p53 remains controversial in stage T1, grade III (T1GIII) transitional cell carcinomas (TCC) of the bladder. Recent studies have reported increased expression of cyclooxygenase-2 (COX-2) in bladder cancer. The prognostic values of p53 and COX-2 were compared in T1GIII TCC of the bladder. Materials and methods: Among 57 consecutive patients, diagnosed with T1GIII TCC of the bladder by transurethral resection (TURB), 37 were eligible for this study. Exclusion criteria included; the first TURB performed elsewhere, no or inadequate (less than 6 weeks) bacillus Calmette-Guerin treatment and postoperative follow-up of less than 1 year. The expressions of p53 and COX-2 were evaluated by immunohistochemical staining of TURB tissues. Possible correlations of the p53 and COX-2 expressions with the clinicopathological features, such as age, shape and multiplicity of tumor, recurrence and progression, were examined. Results: During a mean follow-up of 27 months, the disease recurred in 43.2% and progressed in 16.2%. Of the 37 specimens, 31 (83.8%) and 16 (43.2%) stained positive for COX-2 and p53 expressions, respectively. There were no significant differences in age, shape and multiplicity of the tumors, recurrence-free survival and progression-free survival between the p53 positive and negative groups. However, the recurrence-free and progression-free survivals were significantly lower in the COX-2 positive than in the COX-2 negative group (p=0.049 and p=0.027, respectively). When combined, p53 and COX-2 more accurately predicted recurrence than COX-2 alone (p=0.036), but not the progression (p=0.776). Conclusions: In the pathologically homogeneous group of T1GIII TCC of the bladder, COX-2 was superior to p53 in predicting the prognosis.

Original languageEnglish
Pages (from-to)785-791
Number of pages7
JournalKorean Journal of Urology
Volume46
Issue number8
Publication statusPublished - 2005 Aug 1

Fingerprint

Cyclooxygenase 2
Urinary Bladder Neoplasms
Transitional Cell Carcinoma
Urinary Bladder
Recurrence
Disease-Free Survival
Mycobacterium bovis
Neoplasms
Staining and Labeling

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Hong, Sung Joon ; Lee, Joong Shik ; Chung, Byung Ha ; Kwon, Soo Mee ; Kim, Sun Il. / Prognostic value of cyclooxygenase-2 and p53 expression in stage T1 grade III bladder cancer. In: Korean Journal of Urology. 2005 ; Vol. 46, No. 8. pp. 785-791.
@article{0823776a65084a47b1bbc71074527354,
title = "Prognostic value of cyclooxygenase-2 and p53 expression in stage T1 grade III bladder cancer",
abstract = "Purpose: The prognostic value of p53 remains controversial in stage T1, grade III (T1GIII) transitional cell carcinomas (TCC) of the bladder. Recent studies have reported increased expression of cyclooxygenase-2 (COX-2) in bladder cancer. The prognostic values of p53 and COX-2 were compared in T1GIII TCC of the bladder. Materials and methods: Among 57 consecutive patients, diagnosed with T1GIII TCC of the bladder by transurethral resection (TURB), 37 were eligible for this study. Exclusion criteria included; the first TURB performed elsewhere, no or inadequate (less than 6 weeks) bacillus Calmette-Guerin treatment and postoperative follow-up of less than 1 year. The expressions of p53 and COX-2 were evaluated by immunohistochemical staining of TURB tissues. Possible correlations of the p53 and COX-2 expressions with the clinicopathological features, such as age, shape and multiplicity of tumor, recurrence and progression, were examined. Results: During a mean follow-up of 27 months, the disease recurred in 43.2{\%} and progressed in 16.2{\%}. Of the 37 specimens, 31 (83.8{\%}) and 16 (43.2{\%}) stained positive for COX-2 and p53 expressions, respectively. There were no significant differences in age, shape and multiplicity of the tumors, recurrence-free survival and progression-free survival between the p53 positive and negative groups. However, the recurrence-free and progression-free survivals were significantly lower in the COX-2 positive than in the COX-2 negative group (p=0.049 and p=0.027, respectively). When combined, p53 and COX-2 more accurately predicted recurrence than COX-2 alone (p=0.036), but not the progression (p=0.776). Conclusions: In the pathologically homogeneous group of T1GIII TCC of the bladder, COX-2 was superior to p53 in predicting the prognosis.",
author = "Hong, {Sung Joon} and Lee, {Joong Shik} and Chung, {Byung Ha} and Kwon, {Soo Mee} and Kim, {Sun Il}",
year = "2005",
month = "8",
day = "1",
language = "English",
volume = "46",
pages = "785--791",
journal = "Korean Journal of Urology",
issn = "2005-6737",
publisher = "Korean Urological Association",
number = "8",

}

Prognostic value of cyclooxygenase-2 and p53 expression in stage T1 grade III bladder cancer. / Hong, Sung Joon; Lee, Joong Shik; Chung, Byung Ha; Kwon, Soo Mee; Kim, Sun Il.

In: Korean Journal of Urology, Vol. 46, No. 8, 01.08.2005, p. 785-791.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic value of cyclooxygenase-2 and p53 expression in stage T1 grade III bladder cancer

AU - Hong, Sung Joon

AU - Lee, Joong Shik

AU - Chung, Byung Ha

AU - Kwon, Soo Mee

AU - Kim, Sun Il

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Purpose: The prognostic value of p53 remains controversial in stage T1, grade III (T1GIII) transitional cell carcinomas (TCC) of the bladder. Recent studies have reported increased expression of cyclooxygenase-2 (COX-2) in bladder cancer. The prognostic values of p53 and COX-2 were compared in T1GIII TCC of the bladder. Materials and methods: Among 57 consecutive patients, diagnosed with T1GIII TCC of the bladder by transurethral resection (TURB), 37 were eligible for this study. Exclusion criteria included; the first TURB performed elsewhere, no or inadequate (less than 6 weeks) bacillus Calmette-Guerin treatment and postoperative follow-up of less than 1 year. The expressions of p53 and COX-2 were evaluated by immunohistochemical staining of TURB tissues. Possible correlations of the p53 and COX-2 expressions with the clinicopathological features, such as age, shape and multiplicity of tumor, recurrence and progression, were examined. Results: During a mean follow-up of 27 months, the disease recurred in 43.2% and progressed in 16.2%. Of the 37 specimens, 31 (83.8%) and 16 (43.2%) stained positive for COX-2 and p53 expressions, respectively. There were no significant differences in age, shape and multiplicity of the tumors, recurrence-free survival and progression-free survival between the p53 positive and negative groups. However, the recurrence-free and progression-free survivals were significantly lower in the COX-2 positive than in the COX-2 negative group (p=0.049 and p=0.027, respectively). When combined, p53 and COX-2 more accurately predicted recurrence than COX-2 alone (p=0.036), but not the progression (p=0.776). Conclusions: In the pathologically homogeneous group of T1GIII TCC of the bladder, COX-2 was superior to p53 in predicting the prognosis.

AB - Purpose: The prognostic value of p53 remains controversial in stage T1, grade III (T1GIII) transitional cell carcinomas (TCC) of the bladder. Recent studies have reported increased expression of cyclooxygenase-2 (COX-2) in bladder cancer. The prognostic values of p53 and COX-2 were compared in T1GIII TCC of the bladder. Materials and methods: Among 57 consecutive patients, diagnosed with T1GIII TCC of the bladder by transurethral resection (TURB), 37 were eligible for this study. Exclusion criteria included; the first TURB performed elsewhere, no or inadequate (less than 6 weeks) bacillus Calmette-Guerin treatment and postoperative follow-up of less than 1 year. The expressions of p53 and COX-2 were evaluated by immunohistochemical staining of TURB tissues. Possible correlations of the p53 and COX-2 expressions with the clinicopathological features, such as age, shape and multiplicity of tumor, recurrence and progression, were examined. Results: During a mean follow-up of 27 months, the disease recurred in 43.2% and progressed in 16.2%. Of the 37 specimens, 31 (83.8%) and 16 (43.2%) stained positive for COX-2 and p53 expressions, respectively. There were no significant differences in age, shape and multiplicity of the tumors, recurrence-free survival and progression-free survival between the p53 positive and negative groups. However, the recurrence-free and progression-free survivals were significantly lower in the COX-2 positive than in the COX-2 negative group (p=0.049 and p=0.027, respectively). When combined, p53 and COX-2 more accurately predicted recurrence than COX-2 alone (p=0.036), but not the progression (p=0.776). Conclusions: In the pathologically homogeneous group of T1GIII TCC of the bladder, COX-2 was superior to p53 in predicting the prognosis.

UR - http://www.scopus.com/inward/record.url?scp=23944511336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944511336&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:23944511336

VL - 46

SP - 785

EP - 791

JO - Korean Journal of Urology

JF - Korean Journal of Urology

SN - 2005-6737

IS - 8

ER -